"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Pentazocine is a potent analgesic which when administered orally is approximately equivalent, on a mg for mg basis, in analgesic effect to codeine. Two caplets of TALWIN Compound (pentazocine and aspirin) when administered orally have the additive analgesic effect equivalent to 25 mg of TALWIN plus 650 mg of aspirin. TALWIN Compound (pentazocine and aspirin) provides the analgesic effects of pentazocine and the analgesic, anti-inflammatory, and antipyretic actions of aspirin.
Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine, meperidine, and phenazocine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1 / 50 the antagonistic activity of nalorphine. It also has sedative activity.
Last reviewed on RxList: 1/28/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Talwin Compound Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.